Changing the levels of neurotrophins in the spinal cord micro-environment after nervous system injury has been proposed to recover normal function, such that behavioral response to peripheral stimuli does not lead to chronic pain. We have investigated the effects of recombinant adenoassociated viral (rAAV)-mediated over-expression of brainderived neurotrophic factor (BDNF) in the spinal cord on chronic neuropathic pain after unilateral chronic constriction injury (CCI) of the sciatic nerve. The rAAV-BDNF vector was injected into the dorsal horn at the thirteenth thoracic
Introduction
Studies that focused on the induction and development of neuropathic pain and its relation to spinal nociceptive events following nerve injury have proposed the imbalance of excitatory and inhibitory systems, 1 activation of 'silent' glutamatergic synapses, 2 with accompanying changes in intracellular Ca2+, 3 and loss or down-regulation of the inhibitory ␥-amino butyric acid (GABA) in dorsal horn interneurons, 4, 5 as likely mechanisms. Even with significant debate concerning the action of neurotrophins on the development of neuropathic pain, 6, 7 other roles for endogenous neurotrophins in the dorsal horn and dorsal root ganglion (DRG) in the development of chronic pain has only been recently appreciated. 8 A role for brain-derived neurotrophic factor (BDNF) to affect chronic pain may be related to its stimulation of two major endogenous antinociceptive and inhibitory neurotransmitter systems in the spinal cord: the descending modulatory serotonergic (5HT) system and the dorsal
with a similar injection of a control rAAV-GFP vector (green fluorescent protein) or saline. In situ hybridization for BDNF demonstrated that both dorsal and ventral lumbar spinal neurons contained an intense signal for BDNF mRNA, at 1 to 8 weeks after vector injection. There was no similar BDNF mRNA over-expression associated with either injections of saline or rAAV-GFP. These data suggest that chronic neuropathic pain is sensitive to early spinal BDNF levels after partial nerve injury and that rAAV-mediated gene transfer could potentially be used to reverse chronic pain after nervous system injuries in humans.
Gene Therapy (2002) 9, 1387-1395. doi:10.1038/sj.gt.3301814 horn inhibitory GABA system. BDNF is a potent survival and differentiation factor for many developing and injured neuronal systems, 9 including CNS GABAergic 10 and serotonergic (5HT) neurons. 11 It is anterogradely transported by DRG C-fiber afferents 12 to their terminal targets in spinal dorsal laminae I and II, and to a lesser extent laminae IV/V and laminae X, 13 where BDNF is concentrated at synaptic terminals. The ability to alter BDNF levels with chronic delivery of exogenous neurotrophic factors, such as BDNF to the CNS, is problematic as they will not cross the blood-brain barrier and must be directly injected or chronically infused. Chronic delivery of BDNF 69 and 5HT 53, 54 from subdurally grafted bioengineered neuronal cells, functioning as cellular minipumps, resulted in an attenuation of the altered sensory behaviors in neuropathic pain. These findings suggest that a chronic source of BDNF alone might directly affect the reversal of those behaviors after partial nerve injury. However, cell-based delivery, with its problems of immune rejection and imprecise placement of cell grafts, might be better supplanted by direct gene transfer of BDNF to the injured spinal cord.
Efficient gene transfer and stable transgene expression into host CNS are two key features of the rapidly developing technology of gene transfer for CNS injur-ies.
14 Adeno-associated virus (AAV)-derived vectors 15 are promising candidates for gene therapy because of their ability to mediate highly efficient gene transfer into several nondividing cell types, including neurons, 16 without inducing pathogenic or inflammatory side-effects. 17 Long-term expression of transgenes in tissues after AAV vector transduction, including the spinal cord, 18 has been documented for periods of at least 18 months. 19, 20 Transgene expression after AAV infection can induce a variety of cell-specific changes in the host genome, [21] [22] [23] including morphological changes related to reversal of defective CNS degeneration or behavior 21, 23 by the presence of the transgene 24, 25 such as BDNF. Utilizing recombinant adeno-associated viral BDNF/WPRE (rAAV/BDNF/WPRE)-mediated overexpression of BDNF 26, 27 near the spinal lumbar dorsal horn after partial nerve injury, we hypothesized that chronic spinal BDNF over-expression would alleviate chronic neuropathic pain. This would provide an alternate method to cell transplants that supply the antinociceptive agent. Such gene transfer methods would circumvent certain cell-based problems, such as transplant rejection, stimulation of the immune system, and imprecise placement of foreign cellular material in the cord. In the present study, we describe the alleviation of tactile allodynia and thermal hyperalgesia induced after a chronic constriction injury (CCI) of the sciatic nerve by spinal injection of a rAAV/BDNF/WPRE vector 1 week after the injury. Preliminary results of these data have been reported. 28 This approach to chronically synthesize and deliver BDNF into the CNS may provide a useful model for the creation of similarly derived antinociceptive AAV vectors and their therapeutic use for chronic pain.
Results

Vectors used for transduction of the spinal cord
The genetic backbone of rAAV vectors used to infect the spinal cord are illustrated in Figure 1 . Both had infectious titers of about 10 8 IU/ml. In contrast, injection of the rAAV/BDNF/WPRE vector resulted in very intense signal for BDNF mRNA in transverse sections 4 (g) and 8 weeks (h) after rAAV vector injection. The BDNF over-expressing spinal neurons were distributed in dorsal (g, h) and ventral areas (e).
Thermal hyperalgesia after CCI and injection of rAAV vectors
The measure of sensitivity to noxious heat in animals after nerve injury and gene transfer and over-expression of BDNF in the spinal cord is shown in Figure 3 . In control animals without surgery, no difference was observed between operated and unoperated hindlimbs in the latency of withdrawal over 8 weeks. The range of latency scores was 6.3 to 16.9 s in the right hindpaw and 6.1 to 17.6 s in the left hindpaw at 2 weeks in control animals. After CCI alone, or CCI/saline a vigorous hypersensitivity to heat was observed in the ligated paw at 1 week after injury that reached maximal at 1 to 2 weeks, and did not recover by 8 weeks. At 2 weeks after CCI, the range of latency scores was 5.0 to 10.9 s in the ligated (right) hindpaw and 6.5 to 18.2 s in the non-ligated (left) hindpaw. A similar sensitivity was seen in the ligated paw before injection of rAAV/BDNF/WPRE vector 1 week after CCI. However, 1 week after vector injection (2 weeks after CCI), the sensitivity in the ligated hindpaw had almost completely disappeared. The range of latencies was 6.8 to 16.8 s in the ligated hindpaw and 7.0 to 16.5 s in the non-ligated hindpaw at 2 weeks after injection of rAAV/BDNF/WPRE. After injection of control rAAV/GFP/WPRE, the hypersensitivity observed after CCI in the ligated hindpaw remained nearly unchanged for 8 weeks after the CCI. The range of latency scores at 1 week after control gene transfer was 4.1 to 11.1 s in the ligated hindpaw, and 6.8 to 18.1 s in the non-ligated hindpaw.
Tactile allodynia after CCI and injection of rAAV vectors
The effects of injections of rAAV/BDNF/WPRE and rAAV/GFP/WPRE on tactile allodynia after CCI are shown in Figure 4 . All animals were examined 1 week before CCI and for 8 weeks after CCI for foot withdrawal in response to stimulation with a graded series of von Frey hairs as described in Materials and methods. A significant response appeared in the ligated hindpaw 1 week Gene Therapy after CCI alone, that did not resolve during the 8 weeks after surgery. The near maximum nociceptive effect appeared in the ligated paw versus the non-ligated paw at 2 to 3 weeks following CCI, with the range of raw latency scores for the ligated paw being 0.025 to 0.675 g, with 1.22 to 3.55 g in the non-ligated paw. At the same time period, the scores for the uninjured control animals varied from 1.20 to 3.60 g in either paw. However, 1 week after injection of rAAV/BDNF/WPRE near the lumbar spinal cord after CCI , very little mechanical sensitivity was observed. At this time period, the range of raw latency scores in the ligated paw varied from 0.49 to 3.60 g, with 3.90 to 4.08 g in the non-ligated paw. Injection of the control rAAV/GFP/WPRE vector had no significant effect on the induction of mechanical allodynia by CCI. At this same time period, 1 week after injection of the control rAAV, 2 weeks after CCI, the range of raw latency scores in the ligated paw varied from 0.030 to 0.69 g, and 1.20 to 3.60 g in the non-ligated paw.
f). Those cells which contained the positive DIG signal (blue) also double-labeled for NeuN (f) (arrows), while only NeuNlabeled cells are seen when the sense probe was used (b, brown signal). Transverse sections of cords injected with saline vehicle (d) contained no significant DIG signal; while those injected with the rAAV/GFP vector contained only background DIG-labeled cells (c). In contrast, transverse sections from cords injected with rAAV/BDNF resulted in many cells with intense signal at 4 (g) and 8 weeks after injection (h). Magnification: bar, 150 m (a, e); bar, 250 m (b, f); bar, 200 m (c, d, g, h).
Figure 3 Thermal hyperalgesia after CCI and injection of rAAV vectors. Animals were either left unoperated (-᭺-), given the CCI (-¼-), or injected with rAAV/BDNF/WPRE (-̆-) or rAAV/GFP/WPRE vectors (-̅
-
Figure 4 Tactile allodynia after CCI and injection of rAAV vectors. Adult female rats were either left unoperated (-᭺-), given the CCI (-¼-), or injected with rAAV/BDNF/WPRE (-̆-) or rAAV/GFP/WPRE vectors (-̅
Tactile hyperalgesia after CCI and injection of rAAV vectors
The effects of injections of rAAV/BDNF/WPRE and rAAV/GFP/WPRE after CCI on tactile hyperalgesia, or paw pinch, is shown in Figure 5 . Naive animals demonstrated a similar sensitivity in each hindpaw, with the range of latency scores 8.0 to 13.0 in the left paw and 7.0 to 15.0 in the right paw. One week after CCI, the maximum response to paw pinch was seen in the ligated hindpaw and this level of hypersensitivity continued throughout the 8 weeks after CCI. The range of raw latency scores at 1 week after CCI for the ligated hindpaw was 4.0 to 7.0, and 8.0 to 15.0 in the non-ligated hindpaw. The injection of rAAV/BDNF/WPRE, placed 1 week after CCI, potently reversed the nociception in the ligated hindpaw 2 weeks after gene transfer. At 2 weeks after injection, the range of raw latency scores was 8.0 to 14.0 for the ligated paw, and 7.0 to 15.0 for the non-ligated hindpaw. In contrast, after injection of the rAAV/GFP/WPRE vector, the hypersensitivity to paw pinch was not reversed throughout the 8-week course of the experiment. At 2 weeks after injection, the raw latency scores was 3.0 to 7.0 for the ligated hindpaw, and 9.0 to 15.0 in the non-ligated hindpaw.
Figure 5 Mechanical hyperalgesia after CCI and injection of rAAV vectors. Adult female rats were either left unoperated (-᭺-), given the CCI (-¼-), or injected with rAAV/BDNF/WPRE (-̆-) or rAAV/GFP/WPRE vectors (-̅
Discussion
BDNF is known to stimulate two major endogenous antinociceptive and inhibitory neurotransmitter systems in the spinal cord: the descending modulatory serotonergic (5HT) system and the dorsal horn inhibitory GABA system. BDNF has been demonstrated to directly rescue CNS GABA neurons and stimulate GABA neurotransmitter synthesis. [29] [30] [31] [32] Exogenous BDNF has been seen to have a direct positive effect on both uninjured 33 and injured 34 serotonergic neurons in the brainstem, increasing 5HT synthesis and promoting regeneration of 5HT-axons, respectively. Transplants of BDNF-secreting cells in the subarachnoid space after nerve injury has been shown to restore the endogenous GABA system within 1 week after grafting. 35 Infusion of BDNF into the midbrain has a significant antinociceptive effect with accompanying enhanced serotonergic activity in the brain and spinal cord. 33 Delivery of the BDNF gene by AAV-mediated gene transfer, and increased spinal BDNF levels, related to BDNF gene over-expression which supply BDNF to the pain pathways in the dorsal spinal cord could prove to have therapeutic value. 36 The best common explanation for the changes in intraspinal biochemistry to account for the chronic pain that various peripheral and central injuries produce is the loss of inhibitory tone, or loss of modulation by the GABAreleasing interneurons in the spinal cord. 4, 5, [37] [38] [39] [40] Whether such loss of GABA synthesis is due to excitotoxic cell death of GABA interneurons or temporary or permanent alterations in the neurotransmitter's synthesis, is not known, but neurotrophins such as BDNF may act directly to intervene in cell death and/or regulate GAD enzyme activity, as has been seen with BDNF and other GABA cells. [29] [30] [31] [32] Assigning only a antinociceptive function for endogenous BDNF in neuropathy is difficult. Neurotrophic factors such as BDNF, and NT-3 play a significant role in the development, and perhaps maintenance, of the sensory neurons responsive to temperature and tactile pain, evidenced in neurotrophin-knockout mice. 41 Both motorneurons and sensory neurons express trkB. [42] [43] [44] Since BDNF is localized to dense core vesicles in terminals in the dorsal horn, 45 it could be released with synaptic activation of afferents 46 and modulate transmission of sensory stimuli. In the peripheral inflammation model of pain, rather than the partial nerve injury model used here, endogenous BDNF release may play a very different role in central sensitization, with increased NMDA receptormediated excitability to nociceptive inputs in spinal neurons 47 and induction of c-fos 48 after treatment with exogenous BDNF. Similar regulation of excitatory synaptic strengths by exogenous BDNF has been seen in cortical circuits. 49 This is in contrast to nerve injury where BDNF is able to reduce the GABA A receptor-mediated conductances in axotomized cutaneous afferents 50 suggesting that BDNF may facilitate nociceptive input from those terminals into the dorsal horn after nerve injury.
There is significant evidence that exogenous BDNF infusion near the spinal cord provides potent antinociception 51 by increasing the synthesis and release of serotonin (5HT) in descending raphe serotonergic/ peptidergic neurons providing inhibitory modulation of the dorsal horn. 11 Recently, exogenous BDNF was seen to have a direct positive effect on both uninjured 33 and injured 34 serotonergic neurons in the brainstem, increasing 5HT synthesis and promoting regeneration of 5HT-axons, respectively. BDNF has also been demonstrated to increase 5HT synthesis in raphe neurons in vitro by increasing expression of tryptophan hydroxylase (TPH; the rate-limiting enzyme for 5HT synthesis). 52 Lumbar subarachnoid grafts of cells that synthesized both BDNF and 5HT were able to reverse chronic neuropathic pain after CCI, 53 and neuropathic pain after dorsal hemisection injury of the spinal cord. 54, 55 Serotonergic inhibition of primary afferents, 56 individual spinal neurons, 57 as well as the presence of ascending serotonergic sensory pathways, 58 suggest that changes in the serotonergic systems might facilitate or inhibit the development of chronic pain after PNS and CNS injury. 59 Activation of serotonin receptors and the tail-flick response 60 suggests that other, non-serotonergic systems or their interaction with the descending serotonin system may play an even more important role in nociceptive responses.
It is unclear what therapeutic dose of BDNF may be required to affect neuropathic pain and how these levels of BDNF may affect sensory behaviors chronically in the absence of injury, since spinal levels of BDNF in vivo were not measured here. A group of animals which had no nerve injury but received rAAV/BDNF/WPRE injections, did not demonstrate any changes in sensory behaviors (data not shown) after gene transfer, and partial nerve injury may require increased BDNF levels to reverse neuropathic pain. Here we show definite rAAV/BDNF-mediated BDNF over-expression in many ventral and dorsal spinal neurons of the lumbar cord associated with pain-processing pathways. Endogenous BDNF expression, seen in the saline-and rAAV/GFPinjected cords is low, and mostly limited to the ventral motor neurons, not likely to have an immediate effect on dorsal pain pathways from damaged afferent sciatic nerve input. It is likely, even if the dose of BDNF supplied by over-expression is low, its probable effects are to prevent the induction phase of neuropathic pain, eg probably by rescue of the loss of other endogenous inhibitory systems.
There are a few issues surrounding the eventual development and use of gene transfer for antinociceptive therapy, since these and other studies merely model the first steps in the use of gene transfer for pain. The problems to be overcome include the complication of lack of control of gene expression, 61 especially with potent neurotrophins such as BDNF. The clinical presentation of traumatic nervous system damage and the ensuing development of persistent pain requires some appreciation for the possibilities of gene transfer as a method to provide antinociception.
In summary, the objective of these studies was to cause intraspinal rAAV-mediated over-expression of the neurotrophin BDNF to alter the outcome of the behavioral effects of nerve injury that mimic the evoked hypersensitivity reported as painful in humans after similar nerve injuries. It is known that infusion of BDNF into the adult brain stem provides potent analgesia. 11 However, gene
Gene Therapy transfer eliminates problems associated with exogenous infusion pumps, such as lability of neurotrophins, infection at the catheter tip and initial high dose of agents.
More recent use of cell therapy and grafted cells near the spinal pain-processing areas has its own complications from the often poor viability of the transplanted cells, and limited gene expression. However, cell lines can be engineered to synthesize a single factor, such as the neurotrophin BDNF, and used for cell therapy, at doses that might not be expected to influence peripheral or supraspinal pain-processing centers. Similarly, eventual use of gene transfer for chronic pain requires testing each antinociceptive molecule expressed by the spinal environment for its potential safety and efficacy in animal models.
Materials and methods
Recombinant adeno-associated viral vector production
The AAV vectors used in these studies were constructed by inserting either the rat brain-derived neurotrophic factor (BDNF) or 'humanized' green fluorescent protein (GFP) 62 cDNA into the AAV vector plasmid pTR-UF. 63 Briefly, BDNF cDNA was cloned into pcDNA I/AMP yielding the plasmid pc5-BDNF. Subsequently, pTRCMVbdnf and pTR-CMVgfp were constructed by insertion of the corresponding transgene expression casettes between the ITRs of pTR-UF. Downstream of the transgene cDNA, the cis-acting woodchuck hepatitis virus posttranscriptional regulatory element (WPRE) was cloned into enhance vector-derived transgene expression. 64 The construction of the helper plasmid pDG, needed for the production of recombinant AAV vector particles, was described previously. 65 Recombinant AAV particles were produced as described by the method of Hermens et al. 66 Briefly, the vector plasmid pTR-CMVbdnf or pTR-CMVgfp and the helper plasmid pDG were cotransfected into 293 cells using calcium phosphate precipitation. The medium was replaced after 6 h by fresh DMEM containing 10% FCS and the cells were incubated for 48 h at 37°C and 5% CO 2 . Next, the cells were dislodged, harvested and freeze-thawed three times to release the AAV particles from the cells. Cell debris was removed using low-speed centrifugation. The supernatant was loaded on a Matrex Cellufine sulphate bead column (Amicon, Danvers, MA, USA). After several washings with phosphate-buffered saline (PBS), the virus was eluted from the column with PBS containing 1 M NaCl. Next, viral particles were banded on a Iodixanol (Nycomed Pharm, Oslo, Norway) density gradient using ultracentrifugation and fractions of about 300 l were collected from the bottom of the gradient. To reduce viscosity of the Iodixanol, rAAV-fractions were diluted 10 times with PBS and reconcentrated on a Centricon-100 concentrator (Amicon). The rAAV titers were determined by an infectious unit (IU) center assay. 67 The infectious titer for the rAAV/GFP/WPRE was 7 × 10 8 IU/ml; the infectious titer for rAAV/BDNF/WPRE was 5 ×10
8 IU/ml.
Chronic constriction injury (CCI)
The surgery to produce CCI was first described by Bennet and Xie. 68 This model of injury has been used to test the effects of spinal intrathecal cell transplants that secrete BDNF to relieve the pain-related behaviors, 69 and the same pain model was subsequently used before injection of rAAV/BDNF for over-expression of BDNF in the spinal cord. Under ketamine/xylazine/acepromazine anesthesia, the right common sciatic nerve was exposed at the level of the middle thigh by blunt dissection through the biceps femoris. Proximal to the nerve's trifurcation, a 5-7 mm of nerve was freed of adhering tissue and four ligatures (4.0 chromic gut) were tied loosely around it with about 1 mm spacing. Care was taken to tie the ligatures so that the diameter of the nerve was barely constricted. The incision was closed in layers and the entire surgery was repeated, minus the ligatures, on the left side to create a sham-operated nerve.
All surgical interventions and pre-and post-surgical animal care, and euthanasia was in accordance with the Laboratory Animal Welfare Act, Guide for the Care and Use of Laboratory Animals (NIH, DHEW Pub. No. 78-23, Revised, 1978) and guidelines provided by the Animal Care and Use Committee of the University of Miami, Miami, Florida which conform to the guidelines on the study of pain in awake animals established by the International Association for the Study of Pain. 70 
Injection of rAAV vectors
Injection of rAAV vectors into the lumbar spinal cord is a modification of methods described previously. 18 Adult Wistar Furth females that had been given the CCI surgery 1 week previously and had demonstrated significant behavioral hypersensitivity to tactile and thermal stimuli were used for injection of AAV vectors. Animals were either injected with saline only, the AAV/BDNF or the AAV/GFP vector. Animals were anesthetized with a mixture of ketamine, xylazine, and acepromazine, 0.65 ml/kg. The skin overlying the lower thoracic vertebra was incised, and a hemi-laminectomy was performed at the T12 level to expose the first lumbar segment of the spinal cord. The dura was initially punctured with a 31G needle. The rAAV stock (titer matched to 5 × 10 8 IU/ml) was injected 1.0 mm deep into the right dorsal spinal gray matter, using a pulled-glass micropipette (100 m tip) connected to a 5 l Hamilton syringe. One microliter was injected over a 2-min interval, with the pipette left in place for 1 min to prevent backflow. The muscle layers and skin were closed over the injection site. Animals were allowed to recover at 37°C for 12 h, after which time they were returned to the animal care facility, and housed at one per cage with rat chow and water ad libitum on a 12/12 h light/dark cycle.
Tissue preparation for in situ hybridization
At 1, 4 and 8 weeks after CCI and injection of rAAV vectors, animals were deeply anesthetized with an intraperitoneal injection of a mixture of ketamine, xylazine, and acepromazine, 0.65 ml/kg, spinal cords were rapidly dissected, cryoprotected by soaking in ascending sucrose solutions to 30% (made with DEPC), embedded in Tissue Tek (OCT compound), and snap-frozen in dry ice and stored at Ϫ80°C until the blocks were cut. Consecutive horizontal (sagittal) or transverse cryosections (10-15 m) were cut at Ϫ20°C, collected on to poly-L-lysinecoated microscope slides (ProbeOn.Plus; Fisher, Pittsburgh, PA, USA), stored at Ϫ80°C until used for nonradioactive in situ hybridization, or double labeling combining in situ hybridization, followed by immunohistochemistry for the neuronal marker NeuN.
Non-radioactive in situ hybridization for BDNF overexpression Digoxigenin (DIG)-labeled cRNA probes, message complementary (antisense), and noncomplementary (sense), were generated from completely linearized cDNA template using the appropriate RNA polymerases: antisense, HindIII digestion and SP6 RNA polymerase and sense, XhoI digestion and T7 RNA polymerase utilizing Roche's DIG RNA Labeling Kit (SP6/T7). To enhance tissue penetration and avoid nonspecific background, the cRNA probes were adjusted to an average length of 100-200 bases by alkaline hydrolysis for 20 min at 60°C before use. 71 Riboprobes were quantified with a known amount of control DIG-labeled RNA and utilizing Roche's DIG Quantification Teststrips and DIG Wash & Block Buffer Set, following the manufacturer's recommendations.
Methods for nonradioactive in situ hybridization for BDNF riboprobes were adapted from those previously described, 72 with minor modifications, 73 utilizing the DIG Nucleic Acid Detection Kit from Roche, following the manufacturer's recommendations. Briefly, cryostat sections freshly obtained from unfixed tissue were fixed in 4% paraformaldehyde (PFA) in 0.1 M phosphate buffered saline (PBS, pH 7.4) before acetylation with 0.25% acetic anhydride in 0.1 M triethanolamine. Prehybridization utilizing 150 l of the hybridization solution on each slide (containing 50% formamide, 5 × Denhardt's solution, 5 × SCC, 250 g/ml bakers yeast tRNA, 500 g/ml sheared, heat-denatured herring sperm DNA) was performed for 2 h, at 60°C, in a humidified oven (slides covered with Hybri-slip; Sigma, St Louis, MO, USA) before the solution was replaced with new hybridization solution (containing 50 ng/ml of riboprobe in hybridization solution) and hybridization continued overnight at 60°C in a humidified oven. Stringency washes for optimal specific hybridization signal was as follows: 5 × SSC, 10 min, RT; 5 × SSC, 30 min, 60°C; 2 × SSC, 30 min, 60°C; 0.2 × SSC, 30 min, 60°C; 0.2 × SSC, 10 min, RT. Binding of DIGlabeled RNA hybrids with an anti-DIG Fab fragment (1:1000 dilution) (DIG Nucleic Acid Detection Kit) conjugated to alkaline phosphatase was followed by the color reaction with 5-bromo-4-chloro-3-indolylphosphate (BCIP) as the substrate, with levamisole (1.0 M) added (in 0.1 M Tris-NaCl, 5 mM MgCl 2 ). All tissue sections were incubated with the substrate for an equivalent time period, 12 h, to ensure comparability of signal intensity between treatment groups. Controls, consisting of sections subjected to the complete in situ hybridization procedure, but with no probe added, or hybridized with sense probe for BDNF, exhibited no specific hybridization signal. Some slides were rinsed and subjected to further immunostaining for the NeuN marker to identify spinal neurons over-expressing BDNF mRNA after AAV vector injection at 1 week after vector injection.
Immunohistochemistry
NeuN: In a group of animals different than that used to assess sensory behaviors after AAV/BDNF vector injections, spinal cords collected at 1 week after CCI surgery and vector injections were first processed for in situ hybridization with sense and antisense probes as described above before beginning the immunostaining procedures. Selected representative sections were stained for the neuronal nuclear marker NeuN (1:1000 dilution (of 1 mg/ml) in PBS, pH 7.4), overnight at 4°C, followed by the mouse Vecastain Elite ABC Peroxidase Kit (Vector, Burlingame, CA, USA) with NovaRed Substrate as the chromagen and mounted in Gel/Mount (Biomedia) after antibody staining. The secondary reporter used for NeuN localization was the mouse Elite ABC kit (Vector Laboratories) with substitution of the DAB substrate with NovaRed peroxidase substrate (Vector). Final photo images were taken from stained slides of sections with a Zeiss AxioplanII with Metamorph software at 200 dpi in TIF format and images collected and arranged in Adobe Photoshop.
Behavioral testing
One week before CCI and vector injections, animals were acclimated and trained for 3 days on all behavioral tests, followed by a baseline measure of the tests described below, 1 week before CCI. One week following CCI and every week thereafter, animals were retested. Surgery and sensory testing were done in separate locations, by different experimenters, on animals with unmarked cage cards to assure blinded sensory testing. All animals, injected and non-injected, received near-identical anesthesia and midline incisions near the injection site at the same time point in the experiment, 1 week after CCI. Only animals that demonstrated a vigorous hypersensitivity to tactile and thermal stimuli 1 week after CCI were injected with rAAV vectors 1 day later. Animals were then injected with either saline, or the control rAAV/GFP or the rAAV/BDNF, as described above. A third group of animals received CCI but no spinal injections or saline injections and served as the CCI-alone control group. A fourth group of animals received neither CCI nor injections and served as the naive control animals. A fifth group of animals received rAAV vector injections, but not CCI, and served as AAV vector-only controls. The behavioral data resulting from these animals did not demonstrate results different from the non-injected, noninjured animals, and hence was not included in the data figures. Behavioral testing was repeated for all animals once a week for 8 weeks following CCI and injections. All animals used for behavioral testing were killed after 8 weeks of testing. Another group of animals used to examine long-term transgene expression after CCI were killed at 1, 4 and 8 weeks and were not included with those used for behavioral testing.
Thermal hyperalgesia
Methods for testing thermal hyperalgesia with a Hargreaves device have been described elsewhere. 74 Animals were placed in a clear plexiglass box on an elevated plexiglass floor. Animals were allowed to acclimate for approximately 5 min. A constant intensity, radiant heat source was aimed at the midplantar area of the ligated and sham-operated hind paws. The time, in seconds, from initial heat source activation until paw withdrawal was recorded. Five minutes were allowed between stimulations. Five latency measurements for each paw were recorded at weekly sessions before and after CCI and after gene transfer. For each of the five latency measurements, the score of the sham-operated paw was subtracted from the ligated paw. From these values, a mean difference score for each session was calculated for each experimental animal and used to determine the effects of the different treatments.
Gene Therapy
Tactile allodynia Mechanical allodynia, the occurrence of foot withdrawal in response to normally innocuous mechanical stimuli was tested using a graded series of von Frey hairs. 75 Animals were placed in a plexiglass box with an elevated mesh floor. After the animal was acclimated for 5 min, calibrated Von Frey hairs with ranges from 0.41 to 8.5g were applied perpendicular to the midplantar area of the ligated and sham-operated hindpaw and depressed slowly until bent. The value, in grams, for the minimal, initial hindpaw withdrawal was recorded for each of five trials. A single trial of stimuli consisted of five applications of a von Frey filament within a 10-s period, to ensure that the response was constant. Each session consisted of five trials, repeated at 3-min intervals on each hindpaw. This minimum value for initial response for the sham-operated paw was subtracted from the score for the ligated paw and all five replicate scores were averaged. From these values, a difference score was calculated and used to determine the effects of the different treatments.
Mechanical hyperalgesia
Mechanical pain thresholds to noxious stimulation (paw pinch) after gene transfer and CCI were determined with a modified version of the Randall-Selitto method, 76 using a paw pinch analgesymeter (Stoelting, Wood Dale, IL, USA). A conical stylus with a hemispherical tip (1.2 mm radius) was placed on the middle of the hindpaw dorsal surface. The animal was restrained gently between cupped hands and calibrated pressure of gradually increasing intensity (16 g/s) was applied until the rat withdrew the hind paw. The hind paws were tested alternately at 3-4 min intervals. Five measurements were taken for each side, averaged and difference score computed by subtracting the average of the control side from the average of the ligated side. From these values, a mean difference score for each session was calculated for each experimental animal and used to determine the effects of the different treatments.
Statistical analysis
Statistical significance of all quantitative data was determined with a multivariate analysis of variance (MANOVA). Comparisons of differences between individual means were tested using the Tukey honest significant differences (HSD) method or the unequal N least significant difference (LSD) test. All of the analyses were performed with a commercially available software package (Statistica, Statsoft, 1990) . P values less than 0.05 ( * ) were considered statistically significant.
Chemicals
The following materials were obtained from the indicated sources: Vectastain Elite ABC kits (anti-mouse and antirabbit IgG) from Vector Laboratories; BCIP/NBT substrate, Proteinase K, DIG RNA Labeling Kit (SP6/T7), DIG Quantification Teststrips, DIG Nucleic Acid Detection Kit, High Pure Plasmid Isolation Kit, and DIG Wash & Block Buffer Set, which contained the materials for in situ hybridization with non-radioactive digoxigenin detection of riboprobes were from Roche Molecular Biochemicals (Mannhein, Germany); all restriction enzymes used were from New England BioLabs (Beverly, MA, USA); all other reagents and chemicals were purchased from Sigma Chemical. The mouse anti-Neuronal Nuclei (NeuN) antibody was obtained from Chemicon (Temecula, CA, USA). The NovaRed chromagen used for double-labeling and detection of NeuN (NovaRed Substrate Peroxidase Kit) was obtained from Vector Laboratories. The Matrex Cellufine sulphate was obtained from Amicon (Danvers, MA, USA); Iodixanol from Nycomed Pharm (Oslo, Norway). ProbeOn.Plus microscope slides were obtained from Fischer Scientific. Gel/mount solution was obtained from Biomedia (Foster City, CA, USA). Hybri-slips were obtained from Sigma Chemical.
